These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21496012)

  • 21. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
    Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
    Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. O
    Hiddinga BI; Pauwels P; Janssens A; van Meerbeeck JP
    Lung Cancer; 2017 May; 107():91-99. PubMed ID: 27492578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.
    Walter T; van Brakel B; Vercherat C; Hervieu V; Forestier J; Chayvialle JA; Molin Y; Lombard-Bohas C; Joly MO; Scoazec JY
    Br J Cancer; 2015 Feb; 112(3):523-31. PubMed ID: 25584486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT immunoexpression in adamantinomatous craniopharyngiomas.
    Zuhur SS; Müslüman AM; Tanık C; Karaman O; Oztürk FY; Ozderya A; Ozkayalar H; Aydın Y; Altuntaş Y
    Pituitary; 2011 Dec; 14(4):323-7. PubMed ID: 21318329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
    Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
    Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
    Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MGMT expression and pituitary tumours: relationship to tumour biology.
    McCormack A; Kaplan W; Gill AJ; Little N; Cook R; Robinson B; Clifton-Bligh R
    Pituitary; 2013 Jun; 16(2):208-19. PubMed ID: 22797801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
    Ferriss JS; Atkins KA; Lachance JA; Modesitt SC; Jazaeri AA
    Int J Gynecol Cancer; 2010 Jan; 20(1):120-5. PubMed ID: 20130512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
    Pietanza MC; Kadota K; Huberman K; Sima CS; Fiore JJ; Sumner DK; Travis WD; Heguy A; Ginsberg MS; Holodny AI; Chan TA; Rizvi NA; Azzoli CG; Riely GJ; Kris MG; Krug LM
    Clin Cancer Res; 2012 Feb; 18(4):1138-45. PubMed ID: 22228633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
    Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
    Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
    Medeiros BC; Kohrt HE; Gotlib J; Coutre SE; Zhang B; Arber DA; Zehnder JL
    Am J Hematol; 2012 Jan; 87(1):45-50. PubMed ID: 22052619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
    Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic and molecular profiling predicts response to temozolomide in melanoma.
    Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
    Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.